Skip to main content
Vigonvita Life Sciences Co., Ltd. logo

Vigonvita Life Sciences Co., Ltd. — Investor Relations & Filings

Ticker · 2630 ISIN · CNE1000076N3 HKEX Manufacturing
Filings indexed 50 across all filing types
Latest filing 2026-06-04 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2630

About Vigonvita Life Sciences Co., Ltd.

http://www.vigonvita.cn

Vigonvita Life Sciences Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative small-molecule drugs. The company operates an integrated R&D platform targeting high-need therapeutic areas, specifically neurological and neuropsychiatric disorders, reproductive health, and viral infections. Its comprehensive pipeline includes the oral nucleoside antiviral candidate MINDVY® (VV116), which has been clinically studied for COVID-19 and RSV, and ONVITA® (TPN171). Vigonvita emphasizes high-quality development, evidenced by its participation in significant national programs, including the National Key R&D Program and the Major New Drug Innovation Technology Major Project, often involving international clinical research collaborations.

Recent filings

Filing Released Lang Actions
PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 26, 2026
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a proxy form used to solicit shareholder votes for the Annual General Meeting on June 26, 2026, containing voting instructions and resolutions. It is clearly a proxy solicitation/information statement rather than the AGM materials themselves or actual voting results. Therefore it matches the Proxy Solicitation & Information Statement category.
2026-06-04 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 90% confidence The document is a notice of the company’s Annual General Meeting, outlining the date, venue, and resolutions to be considered (approval of the annual report, election of directors, share mandates, etc.). It does not contain financial statements itself but is an AGM notice. This clearly fits the AGM Information category.
2026-06-04 English
CIRCULAR OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a shareholder circular for an upcoming Annual General Meeting, containing the notice of AGM, explanatory statements on resolutions (annual report approval, director elections, auditor appointment, share mandates, amendments to the articles, etc.), and a proxy form. It is sent to shareholders to inform and solicit votes prior to the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-04 English
PROPOSED CHANGE OF AUDITOR
Regulatory Filings Classification · 45% confidence The document is a formal announcement under Hong Kong Stock Exchange listing rules regarding the proposed change of external auditor. It does not itself present audit findings or financial statements (i.e., it is not an Audit Report AR or Annual Report 10-K), nor is it a notice of dividend, share issue, management change, or other specific category. It constitutes a general regulatory announcement required under the Listing Rules, and thus falls into the fallback category for miscellaneous regulatory filings. Filing code RNS applies.
2026-06-04 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2026
Regulatory Filings Classification · 79% confidence The document is a Monthly Return under Chapter 19B of the HKEX Listing Rules detailing movements in authorised share capital, issued shares, public float confirmation, and compliance confirmations. It is a routine regulatory submission to the exchange and does not constitute a financial report (annual or interim), earnings release, or specialty disclosure (e.g., M&A, director dealing). It is a compliance document falling into the general Regulatory Filings category.
2026-06-04 English
SUPPLEMENTAL ANNOUNCEMENT ON ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Regulatory Filings Classification · 85% confidence The document is a supplemental announcement regarding the Company’s annual results and specifically addresses the inadvertent use of IPO proceeds, subsequent redemption, and remedial actions under the Listing Rules. It is not the full Annual Report itself (10-K), nor is it simply an earnings release or dividend notice. It is a regulatory disclosure to the Hong Kong Stock Exchange and does not fit the more specific categories. Therefore, it should be classified as a general Regulatory Filing (RNS).
2026-06-01 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.